BDSX News
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
TMO, CRCT and SHOP delivered strong gains as Zacks highlighted standout performers across its research portfolios.
Zacks
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
TMO, CRCT and SHOP delivered strong gains as Zacks highlighted standout performers across its research portfolios.
Zacks
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests
BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.
Zacks
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?
Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?
The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
Zacks
Biodesix (BDSX) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
Has Agilon Health (AGL) Outpaced Other Medical Stocks This Year?
Here is how Agilon Health (AGL) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Zacks
Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?
Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet
The consensus price target hints at a 31.9% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates
Biodesix (BDSX) delivered earnings and revenue surprises of +17.44% and +2.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks